Thomson Medical Group (SGX:A50) Valuation Check After Narrower Losses And Higher Half Year Sales

What the latest half year results mean for shareholders Thomson Medical Group (SGX:A50) has just posted half year numbers that show sales of S$213.08 million compared with S$199.06 million a year earlier, alongside a narrower net loss of S$10.25 million. Basic and diluted loss per share from continuing operations came in at S$0.00039, versus S$0.00049 previously. This gives you a sense of how much capital the business is currently consuming per share. See our latest analysis for Thomson Medical Group. At a share price of S$0.06, Thomson Medical Group has seen a 3.45% 3 month share price return and a 30.43% 1 year total shareholder return, suggesting improving sentiment around the business as losses narrow and revenue figures shift. If these results have you reassessing opportunities in healthcare, it could be a good moment to scan a wider field of medical names through our curated list of 106 healthcare AI stocks. With the shares at S$0.06, revenue at S$213.08 million and the group still reporting a net loss, the key question is whether the current price reflects a discount or whether the market is already pricing in an improvement in conditions. Preferred Price-to-Sales Multiple of 3.4x: Is it justified? On our data, Thomson Medical Group is trading on a P/S of 3.4x, which screens as expensive compared with both the Asian healthcare industry and its closest peers. The P/S ratio compares the company’s market value to its revenue. At 3.4x, investors are paying S$3.40 in equity value for every S$1 of annual sales Thomson Medical Group generates. This is a richer tag than the Asian healthcare industry average P/S of 1.5x and also above the peer average of 2.1x. This suggests the market is attaching a higher value to each dollar of Thomson Medical Group’s revenue than it does for many competitors. However, this 3.4x level is close to our estimated fair P/S of 3.6x, so the current ratio is not far from a level the market could reasonably move towards if sentiment or expectations change. Explore the SWS fair ratio for Thomson Medical Group Result: Price-to-sales of 3.4x (OVERVALUED) However, there are still clear risks, including the ongoing net loss of S$44.921 million and weak multi year shareholder returns, which could challenge today’s richer P/S tag. Find out about the key risks to this Thomson Medical Group narrative. Another view on value: what the DCF is saying While the P/S of 3.4x looks expensive against healthcare peers, our DCF model points in a different direction. It indicates a fair value of S$0.11 per share versus the current S$0.06, suggesting that Thomson Medical Group is trading at a sizable discount. Which signal do you trust more? Look into how the SWS DCF model arrives at its fair value. A50 Discounted Cash Flow as at Feb 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Thomson Medical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 221 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of signals leaves you slightly conflicted, that is a healthy place to start. It is worth moving quickly to test your own view against the numbers and context behind 2 key rewards and 1 important warning sign. Looking for more investment ideas? If Thomson Medical Group has sharpened your focus, do not stop here. Use this momentum to compare other opportunities and pressure test your portfolio decisions. Target potential value candidates by scanning our list of 221 high quality undervalued stocks that pair solid fundamentals with more modest pricing. Strengthen the quality of your holdings by checking our solid balance sheet and fundamentals stocks screener (369 results) and see which companies back their stories with robust finances. Add a potential income angle by reviewing our 438 dividend fortresses so you do not miss companies offering higher yields with staying power. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Thomson Medical Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free Analysis